Evaluation of lacrimal duct probing in adults with 0.02% and 0.04% mitomycin-C in primary acquired nasolacrimal duct obstruction: A randomized comparative pilot study.

PURPOSE

The purpose of the study is to evaluate the safety and efficacy of adjunctive use of mitomycin-C (MMC) using two different concentrations 0.2 mg/ml and 0.4 mg/ml for lacrimal duct probing to treat the nasolacrimal duct obstruction (NLDO) in adults.

SUBJECTS AND METHODS

Prospective, an interventional comparative randomized pilot study of lacrimal duct probing conducted in the two study groups 0.02% MMC group ( = 30) and 0.04% MMC group ( = 30) in confirmed primary acquired NLDO of <1-year duration. Patency of lacrimal duct probing confirmed by syringing was compared at 1, 3, and 6-month follow-up in the two study groups, and corresponding subjective improvement of watering was appraised according to Kraft and Crawford grading.

RESULTS

Patency of lacrimal duct probing in 0.02% MMC versus 0.04% MMC group was 66.66%/73.33% ( = 0.71) at 1 month, 46.66%/66.66% ( = 0.09) at 3 months and 46.66%/66.66% ( = 0.03) at 6-month follow-up, respectively. Subjective improvement of watering (no watering and mild watering) observed in 0.02% MMC versus 0.04% MMC group was 46.66%/73.33% ( = 0.03), at 1 month, 66.66%/83.33% ( = 0.13) at 3 months and 56.66%/73.33% ( = 0.17) at 6-month follow-up.

CONCLUSION

Adult lacrimal duct probing with 0.04% MMC was associated with significant higher objective success rate than adult lacrimal duct probing with 0.02% MMC, without added concurrently side effects.